Abstract

We have discussed the use of naftidrofuryl oxalate (Praxilene - Lipha) in peripheral vascular disease, senile dementia and acute cerebrovascular disease several times over the past 16 years. On each occasion we concluded that the evidence that naftidrofuryl gave clinical benefit was at best equivocal, and further trials were needed. We now review recent trials and other new information about the drug.